NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NMN was only considered as a source of cellular energy and an intermediate in NAD+ biosynthesis, currently, the attention of the scientific community has been paid on anti-aging activity and a variety of health benefits and pharmacological activities of NMN which are related to the restoring of NAD+. Thus, NMN has therapeutic effects towards a range of diseases, including age-induced type 2 diabetes, obesity, cerebral and cardiac ischemia, heart failure and cardiomyopathies, Alzheimer’s disease and other neurodegenerative disorders, corneal injury, macular degeneration and retinal degeneration, acute kidney injury and alcoholic liver disease.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
Aging, as a natural process is identified by downregulation of energy production in mitochondria of various organs such as brain, adipose tissue, skin, liver, skeletal muscle and pancreas due to the depletion of NAD+ . NAD+ levels in the body decrease as a consequence of increasing NAD+ consuming enzymes when aging There are three different biosynthesis pathways to produce NAD+ in mammalian cells including de novo synthesis from tryptophan, salt and Preiss-Handler pathways. Among these three pathways, NMN is an interproduct by is involved in NAD+ biosynthesis through salt and Preiss-Handler pathways. The salvage pathway is the most efficient and the main route for the NAD+ biosynthesis, in which nicotinamide and 5-phosphoribosyl-1-pyrophosphate are converted to NMN with the enzyme of NAMPT followed by conjugation to ATP and conversion to NAD by NMNAT. Furthermore, NAD+ consuming enzymes are responsible for degradation of NAD+ and consequence nt formation of nicotinamide as a by-product.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been back by Rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often product sold as functional food than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of N red besumers. a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors over have been studied to diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound ca n be preliminarily determined.
1. Introduction Supplementation of nicotinamide mononucleotide (NMN) to upregulate the level of nicotinamide adenine dinucleotide (NAD+) has been unveiled to be a promising anti-aging intervention. However, it is still a serious challenge to accurately quantify NAD+ intermediates, NMN in particular. This study is powered to introduce a novel method, double isotope-mediated LC-MS/MS methodology (dimeLC-MS/MS), for the precise quantification of NMN in biological samples. 2. Factors affecting the accurate detection of NMN NMN is hard to be accurately detected due to its vulnerability to enzymatic degradation, conversion in sample processing, its complex behaviors in different column and extraction conditions, as well as matrix effect. Specifically, NMN has the properties of high polarity and low volatility, which is easy to dissolve in water but difficult to dissolve in organic solvents. These properties greatly restrict the application of many conventional quantitative analysis methods. Biological samples such as blood carries significant activities of CD38 and CD73 (ecto-5’-nucleotidase), both of which could use NMN as a substrate. The behavior of NMN in the column is very complex probably because of the bipartite nature of its charges so that subtle differences in extraction and column conditions significantly affect the reliable and accurate detection of NMN. 3. Coping strategies of dimeLC-MS/MS to reduce the impact of impact factors To avoid the interference of above-mentioned factors, a prototype column NMN-2 is applied. This column contains C18-based high-purity silica particles which are more capable of binding hydrophilic compounds than carbon particles, improving the ability of separation. Perchloric acid (PCA) is employed since it can efficiently extract NAD+ and NMN from biological samples such as plasma with minimal losses. To adjust for matrix effects, a fixed amount (1 μM) of each isotopic compound is added to biological samples prior to the PCA extraction. 4. The advantages of dimeLC-MS/MS Double isotopic NMN standards, NMN (M + 14) and NMN (M + 5), in the LC-MS/MS-driven methodology can precisely trace the fate of NMN during sample processing, which significantly increases the accuracy and the reliability of NMN measurement in biological samples. Besides, dimeLC-MS/MS can evaluate the extraction efficiency and the absolute concentrations of NMN in different types of biological samples. 5. Conclusion This new LC-MS/MS-driven methodology with double isotopic NMN standards can accurately and reliably measure NMN in biological samples. It can be used for future studies on NMN intake. 6. Reference Unno, Junya et al. “Absolute quantification of nicotinamide mononucleotide in biological samples by double isotope-mediated liquid chromatography-tandem mass spectrometry (dimeLC-MS/MS).” npj aging vol. 10,1 2. 2 Jan. 2024, doi:10.1038/s41514-023-00133-1 Why choose BONTAC? BONTAC is the leader of the global NMN industry. We have the first whole-enzyme catalysis technology in China, and have become the leading enterprise in coenzyme products which are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. Notably, BONTAC is NMN raw material supplier of famous David Sinclair team at the Harvard University. Our services and products are trustworthy. Furthermore, BONTAC has an independent coenzyme engineering technology research center at the provincial level in China and self-owned factories, where the purity ans stability of products can be ensured. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
Introduction Disturbance in hepatic NAD+ metabolism has been manifested as a key factor in the initiation and progression of nonalcoholic fatty liver disease (NAFLD), one of the most common chronic liver disease worldwide. Therapeutic methods aiming to increase NAD+ level are promising for NAFLD treatment. Both NMN and NR can raise NAD+ level. This research is designed to decipher their impacts and underpinned mechanism upon NAFLD based on the transcriptome and metabolome profiling. NMN vs. NR Relative to NR, NMN has an added phosphate group. This added phosphate group makes NMN a larger molecule than NR. Even so, NMN can be transported into cells through specific transporters, such as Slc12a8. NR is intermediate product in the synthesis of NAD+, and NMN is the direct precursor of NAD+. Once inside cells, NMN can be converted to NAD+ under the catalysis of NMNATs, whereas NR needs to be first converted to NMN by NRKs before conversion to NAD+. The efficacy of NMN and NR in alleviating NAFLD In mice with high-fat diet (HFD)-induced NAFLD, NMN or NR is administered through daily oral gavage. It has been found that NMN and NR reduce body weight gain, improve glucose homeostasis, regulate plasma lipid levels, and ameliorate liver injury, oxidative stress and lipid accumulation in mice subjected to HFD feeding. Importantly, both NMN and NR alleviate the HFD-induced NAFLD in mice, as evidenced by the ameliorative hepatic steatosis, inflammation, and fibrosis. The mechanism underlying NAD+ precursor-mediated NAFLD remission Integrated transcriptome and metabolome analysis indicate that arachidonic acid metabolism and linoleic acid metabolism pathway are involved in NMN/NR-induced NAFLD amelioration. Specifically, NMN and NR reduce the saturated fatty acid (palmitic acid, stearate, and arachidic acid) content to protect mice from liver toxicity, alter the arachidonic acid metabolism to regulate immune and inflammatory responses, and restore the decreased polyunsaturated fatty acid (linoleic acid and eicosapentaenoic acid) content in the liver of NAFLD mice. Notably, Mup gene cluster, which can regulate lipid and energy metabolism, may function as a potential target for NMN and NR in the treatment of hepatic lipid accumulation. Furthermore, the CYP450 enzymes might be involved in NMN/NR-mediated arachidonic acid metabolism regulation. Conclusion Both NMN and NR administration significantly modify the hepatic lipid composition via Mup gene cluster, and alter linoleic acid metabolism and arachidonic acid metabolism pathways via CYP450 enzymes, which might mediate NAD+ administration-induced NAFLD remission. Reference Zhang J, Chen F. Integrated transcriptome and metabolome study reveal the therapeutic effects of nicotinamide riboside and nicotinamide mononucleotide on nonalcoholic fatty liver disease. Biomed Pharmacother. Published online May 9, 2024. doi:10.1016/j.biopha.2024.116701 BONTAC NMN and NR BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NMN and NR. BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. BONTAC NMN is patent-grade and has obtained the self-affirmed GRAS certification of FDA. Strikingly, both malate and chloride salt forms of NR are available here. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. At present, BONTAC has become the leading enterprise in niche areas of coenzyme. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible in any way for any claims, damages, losses, expenses or costs arising directly or indirectly from your reliance on the information and material on this website.
Introduction Nicotinamide adenine dinucleotide (NAD+) metabolism is essential for maintaining normal physiological activities, and the decreased NAD+ level is related to various pathologies such as cardiac diseases and ischemia-reperfusion (IR) Injury. Nicotinamide riboside (NR) now appears as optimal NAD+ precursor to mitigate acute cardiac IR injury. Notably, glycolysis activation may be one of the metabolic pathways underlying NR-mediated cardioprotection, and insulin can abrogate this protection. The merits of NR in protecting hearts By virtue of its high bioavailability, its safety in healthy adults or obese patients, and its superiority in efficient NAD+ elevation in humans as compared to other agents, NR has emerged as a leading NAD+ precursor candidate. Up till now, NR has been the only compound to retain cardioprotection in an in vivo IR model with clinically relevant anesthesia. About glycolysis Glycolysis is a metabolic process that allows organisms to obtain energy from glucose under aerobic and anaerobic conditions. During this process, glucose (C6H12O6) can converted into pyruvate (CH3COCOO + H). The released free energy is used to form the high-energy compounds adenosine triphosphate (ATP) and the reduced form of nicotinamide adenine dinucleotide (NADH). Glycolysis is the first step in the process of sugar metabolism in all living cells, which can be regulated to accommodate different metabolic needs. NR-mediated cardio-protection in relation to glycolysis and insulin NR treatment reduces IR-induced cardiac injury in the mouse heart. This protection is associated with glycolysis activation and abrogated in the presence of insulin. Concretely, NR increases NAD+ level, intermediates of glycolysis, pentose phosphate pathway (PPP) and tricarboxylic acid (TCA) cycle, and activates glycolysis in low glycolysis hearts (perfusion of glucose and fatty acid). When glycolysis is already fully activated by high plasma levels of insulin, NR’s protective effect against cardiac IR injury will be diminished or even absent. Conclusion The perioperative metabolic condition (e.g. fasting, low insulin versus non-fasting high insulin conditions) likely dictates the efficacy of NR treatment as therapy against cardiac IR injury. NR may especially offer protection through activation of glycolysis in conditions of low insulin, and its protective potential can diminish in the presence of insulin. Reference [1] Xiao Y, Phelp P, Wang Q, et al. Cardioprotecive Properties of Known Agents in Rat Ischemia-Reperfusion Model Under Clinically Relevant Conditions: Only the NAD Precursor Nicotinamide Riboside Reduces Infarct Size in Presence of Fentanyl, Midazolam and Cangrelor, but Not Propofol. Front Cardiovasc Med. 2021;8:712478. Published 2021 Aug 30. doi:10.3389/fcvm.2021.712478 [2] Xiao Y, Wang Q, Zhang H, et al. Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside. Basic Res Cardiol. 2024;119(3):403-418. doi:10.1007/s00395-024-01042-4 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 170+ BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. BONTAC holds no responsibility for any claims, damages, losses, expenses, costs or liabilities resulting or arising directly or indirectly from your reliance on the information and material on this website.